Lazard (LAZ) Q1 2026 Earnings Transcript

Lazard reported firm-wide adjusted net revenue of $673 million, up 5% year over year, with asset management revenue rising 17% to $309 million and quarterly inflows of $9 billion, the strongest in nearly 20 years. The company announced the acquisition of Campbell Lutyens to build a third global business focused on private capital advisory, targeting about $500 million of combined 2027 revenue and EPS accretion in 2027. Management also declared a $0.50 per share dividend and reiterated a full-year adjusted effective tax rate in the high-20% range, while guiding toward a 65.5% comp ratio for the year.

Analysis

The real story is not the headline revenue beat; it’s that Lazard is trying to re-rate itself from a cyclical advisory shop into a broader private-capital tollbooth. Folding Campbell Lutyens into the platform should improve deal origination density and raise the conversion rate between advisory relationships and fundraising mandates, but the payoff is back-end loaded: the near-term P&L is still hostage to lumpy M&A timing and an elevated compensation structure. That makes the stock less of a single-quarter beat story and more of a 12-24 month operating leverage setup if private capital activity normalizes.

The second-order implication is competitive: Lazard is positioning against specialist fund-placement boutiques and large-bank advisory franchises at the same time, and that combination matters because private markets clients increasingly want a single counterparty across M&A, restructuring, secondaries, and capital raising. If that cross-sell works, it raises switching costs and should compress the moat of smaller PCA firms that lack balance-sheet adjacency and restructuring relationships. It also gives Lazard a better way to monetize sponsor distress if private credit stress broadens beyond software into adjacent sectors.

The main risk is timing, not strategy. A lot of the valuation debate will hinge on whether sponsor M&A and fundraising recover in 2026; if they don’t, investors will keep treating this as an expensive integration story with limited near-term EPS contribution. A subtler risk is that all-stock consideration helps alignment, but if the shares rerate lower before the deferred pieces vest, dilution and retention economics become less attractive than the company is implying.

Key Decisions for Investors

• Long LAZ on a 3-6 month horizon as a self-help + strategic re-rating trade; target upside is driven by multiple expansion if the market starts capitalizing the 2027 revenue mix shift rather than current-quarter earnings. Risk is that the stock stays a 'show me' story until private equity volume improves.
• Pair trade: long LAZ / short GS or MS for 6-12 months if you want exposure to independent advisory share gains and private-capital monetization without taking full large-bank market beta. This works best if sponsor activity remains uneven but cross-sell wins continue to compound.
• Buy LAZ call spreads 6-12 months out instead of outright stock if you want convexity on an integration/mix-shift rerate while limiting downside from delayed deal conversion. Best used ahead of any second-half update on cost actions and post-close integration milestones.
• Short XRX only as a small basket hedge against broader restructuring disappointments, not as a direct call here; if private credit stress broadens, XRX-style situations support LAZ’s restructuring lane and could create a better entry point after initial market optimism fades.
• Watch for a better entry after any pullback tied to weak sponsor M&A prints over the next 1-2 quarters; that would likely be the moment when the market is over-discounting the 2027 earnings power of the Campbell Lutyens combination.